Systematic druggable genome-wide Mendelian randomisation identifies therapeutic targets for Alzheimer's disease.

ABSTRACT:

Background

Alzheimer's disease (AD) is the leading cause of dementia. Currently, there are no effective disease-modifying treatments for AD. Mendelian randomisation (MR) has been widely used to repurpose licensed drugs and discover novel therapeutic targets. Thus, we aimed to identify novel therapeutic targets for AD and analyse their pathophysiological mechanisms and potential side effects.

Methods

A two-sample MR integrating the identified druggable genes was performed to estimate the causal effects of blood and brain druggable expression quantitative trait loci (eQTLs) on AD. A repeat study was conducted using different blood and brain eQTL data sources to validate the identified genes. Using AD markers with available genome-wide association studies data, we evaluated the

SUBMITTER: Su WM 

PROVIDER: S-EPMC10579488 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature